

# Bronwen E Shaw

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8768604/publications.pdf>

Version: 2024-02-01

187  
papers

6,323  
citations

66343

42  
h-index

82547

72  
g-index

193  
all docs

193  
docs citations

193  
times ranked

6609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 112.e1-112.e9.	1.2	4
2	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	1.4	52
3	Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study. <i>IMIR Research Protocols</i> , 2022, 11, e36780.	1.0	4
4	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	1.2	26
5	236 Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 37-38.	0.6	0
6	Incorporating patient-reported outcome data into a hematopoietic cell transplant survival calculator.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7045-7045.	1.6	0
7	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
8	Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 184.e1-184.e13.	1.2	14
9	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 183.e1-183.e7.	1.2	6
10	Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 270.e1-270.e6.	1.2	17
11	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , the, 2021, 8, e185-e193.	4.6	271
12	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.	1.2	2
13	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
14	Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 352.e1-352.e5.	1.2	2
15	Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 494-507.	2.1	14
16	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	1.6	90
17	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	1.2	26
18	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	1.2	10
20	Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 747-757.	1.2	10
21	Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. Blood Advances, 2021, , .	5.2	0
22	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. Blood, 2021, 138, 1772-1772.	1.4	1
23	Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome. Blood, 2021, 138, 421-421.	1.4	0
24	Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic. Blood, 2021, 138, 2846-2846.	1.4	4
25	Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors. Blood, 2021, 138, 4123-4123.	1.4	0
26	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. Blood, 2021, 138, 98-98.	1.4	2
27	Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association. Blood, 2021, 138, 3887-3887.	1.4	0
28	Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans. Blood, 2021, 138, 431-431.	1.4	0
29	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 34-43.	2.0	93
30	Role of Race/Ethnicity in Donor Decisions about Unrelated Hematopoietic Progenitor Cell Donation: Exploring Reasons for Higher Attrition among Racial/Ethnic Minorities. Biology of Blood and Marrow Transplantation, 2020, 26, 593-599.	2.0	22
31	Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. Journal of the American Academy of Dermatology, 2020, 83, 762-772.	1.2	7
32	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
33	Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2365-2371.	2.0	6
34	Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients. EJHaem, 2020, 1, 208-218.	1.0	3
35	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51
36	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1876-1885.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	2.4	7
38	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
39	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	5.2	14
40	Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. <i>Cancer</i> , 2020, 126, 2679-2686.	4.1	11
41	Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e142-e144.	2.0	7
42	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
43	Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e241-e242.	2.0	1
44	Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1828-1832.	2.0	6
45	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41
46	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
47	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
48	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. <i>Bone Marrow Transplantation</i> , 2020, 55, 1975-1984.	2.4	8
49	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
50	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
51	Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative. <i>Blood</i> , 2020, 136, 48-49.	1.4	5
52	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. <i>Blood</i> , 2020, 136, 47-48.	1.4	4
53	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2020, 136, 33-34.	1.4	0
54	Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching. <i>Blood</i> , 2020, 136, 24-26.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 145-150.	2.0	28
56	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	3.0	2
57	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , 2019, 134, 924-934.	1.4	199
58	Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2501-2506.	2.0	10
59	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
60	4-Locus high-resolution HLA allele and haplotype frequencies in admixed population from Nicaragua. <i>Human Immunology</i> , 2019, 80, 417-418.	2.4	0
61	5-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from the Central Valley. <i>Human Immunology</i> , 2019, 80, 413-414.	2.4	0
62	4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from Guanacaste. <i>Human Immunology</i> , 2019, 80, 415-416.	2.4	0
63	4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from African-Caribbean descent. <i>Human Immunology</i> , 2019, 80, 411-412.	2.4	1
64	4-Locus high-resolution HLA allele and haplotype frequencies in Amerindians from Costa Rica. <i>Human Immunology</i> , 2019, 80, 409-410.	2.4	0
65	A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e270-e271.	2.0	1
66	Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1598-1600.	1.6	1
67	Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation. , 2019, , 85-97.		0
68	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1780-1788.	2.4	10
69	Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 443-450.	2.0	84
70	A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplantation Patients, Caregivers, and Families. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1416-1423.	2.0	9
71	“Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries”. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	2.4	51
72	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	5.2	25

#	ARTICLE	IF	CITATIONS
73	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
74	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
75	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
76	Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 22-30.	2.3	12
77	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7
78	Posttransplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Cancer</i> , 2019, 125, 144-152.	4.1	20
79	Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 233-237.	0.6	8
80	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	2.4	14
81	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	2.4	48
82	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	3.5	13
83	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
84	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
85	Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. <i>Bone Marrow Transplantation</i> , 2019, 54, 858-866.	2.4	15
86	Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening. <i>Blood</i> , 2019, 134, 4474-4474.	1.4	0
87	Building a National CML Registry. <i>Blood</i> , 2019, 134, 3440-3440.	1.4	0
88	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
89	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1049-1056.	2.0	98
90	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	3.5	38



#	ARTICLE	IF	CITATIONS
91	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplantation, 2018, 53, 1210-1213.	2.4	7
92	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555.	2.4	75
93	Peripheral Blood Grafts for T Cellâ€“Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1664-1670.	2.0	36
94	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1278-1287.	2.4	25
95	Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1079-1082.	2.4	5
96	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
97	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 228-241.	2.0	43
98	PROMIS measures can be used to assess symptoms and function in longâ€“term hematopoietic cell transplantation survivors. Cancer, 2018, 124, 841-849.	4.1	38
99	Longâ€“term outcomes among 2â€“year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer, 2018, 124, 816-825.	4.1	44
100	In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. Blood Advances, 2018, 2, 1773-1783.	5.2	23
101	Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. Bone Marrow Transplantation, 2018, 53, 1498-1507.	2.4	9
102	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biology of Blood and Marrow Transplantation, 2018, 24, 2040-2046.	2.0	29
103	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.8	47
104	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Biology of Blood and Marrow Transplantation, 2018, 24, 1651-1656.	2.0	18
105	HLA typing-A case-based approach to donor selection. Advances in Cell and Gene Therapy, 2018, 1, e16.	0.9	0
106	Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica, 2018, 103, 1535-1541.	3.5	56
107	EBMTâ€“NIHâ€“CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplantation, 2018, 53, 1401-1415.	2.4	243
108	Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2018, 132, 252-252.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1320-1326.	2.0	10
110	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1327-1334.	2.0	38
111	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
112	Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. <i>Cancer</i> , 2017, 123, 4687-4700.	4.1	50
113	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	4.1	7
114	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
115	Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1646-1650.	2.0	45
116	HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. <i>Blood</i> , 2017, 130, 1089-1096.	1.4	60
117	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20
118	Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 165-171.	2.0	12
119	Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. <i>Blood Advances</i> , 2017, 1, 401-406.	5.2	17
120	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
121	Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1368-1375.	2.0	51
122	Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. <i>Journal of Pediatrics</i> , 2016, 178, 164-170.e1.	1.8	32
123	<sc>BCSH</sc>/<sc>BSBMT</sc>/<sc>UK</sc> clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 380-393.	2.5	40
124	Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. <i>Transfusion</i> , 2016, 56, 1052-1057.	1.6	16
125	Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. <i>British Journal of Haematology</i> , 2016, 172, 360-370.	2.5	79
126	Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the <sc>UK</sc> National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. <i>British Journal of Haematology</i> , 2016, 172, 478-481.	2.5	1



#	ARTICLE	IF	CITATIONS
127	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. JAMA Oncology, 2016, 2, 1583.	7.1	110
128	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biology of Blood and Marrow Transplantation, 2016, 22, 520-527.	2.0	14
129	Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biology of Blood and Marrow Transplantation, 2016, 22, 96-103.	2.0	35
130	European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. Biology of Blood and Marrow Transplantation, 2016, 22, 514-519.	2.0	21
131	Sexual health in hematopoietic stem cell transplant recipients. Cancer, 2015, 121, 4124-4131.	4.1	50
132	Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. Thrombosis Journal, 2015, 13, 21.	2.1	27
133	Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 350-356.	2.0	11
134	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
135	Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2015, 21, 165-171.	2.0	26
136	5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood. Blood, 2015, 126, 270-270.	1.4	7
137	Female donors and donors who are lighter than their recipient are less likely to meet the <sc>CD</sc>34+ cell dose requested for peripheral blood stem cell transplantation. Transfusion, 2014, 54, 2953-2960.	1.6	20
138	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood, 2014, 123, 3655-3663.	1.4	112
139	The frequency of HLA-B*57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. Human Immunology, 2014, 75, 1092-1096.	2.4	10
140	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood, 2014, 124, 2596-2606.	1.4	228
141	High readmission rates are associated with a significant economic burden and poor outcome in patients with grade <sc>III</sc>/<sc>IV</sc> acute <sc>G</sc>v<sc>HD</sc>. Clinical Transplantation, 2013, 27, E56-63.	1.6	32
142	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood, 2013, 121, 197-206.	1.4	123
143	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncology, The, 2012, 13, 366-374.	10.7	289
144	A combined DPA1*4/DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer. Immunogenetics, 2012, 64, 559-569.	2.4	47

#	ARTICLE	IF	CITATIONS
145	Diagnosis and management of chronic graft-versus-host disease. British Journal of Haematology, 2012, 158, 46-61.	2.5	152
146	Diagnosis and management of acute graft-versus-host disease. British Journal of Haematology, 2012, 158, 30-45.	2.5	281
147	Organ-specific management and supportive care in chronic graft-versus-host disease. British Journal of Haematology, 2012, 158, 62-78.	2.5	65
148	The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.. Blood, 2012, 120, 3125-3125.	1.4	0
149	Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. Blood, 2011, 117, 21-25.	1.4	31
150	Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. British Journal of Haematology, 2011, 153, 244-252.	2.5	18
151	Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica, 2011, 96, 942-947.	3.5	75
152	High Absolute T Regulatory Cell Counts and Resistance of CD8 Central Memory Cells to Killing by Fludarabine Predicts for Poor Responses to DLI in the Context of a Pre-DLI Lymphoreduction Strategy. Blood, 2011, 118, 1912-1912.	1.4	16
153	First do no harm. Blood, 2010, 115, 4978-4979.	1.4	8
154	The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. British Journal of Haematology, 2010, 150, 251-258.	2.5	83
155	Permissive HLA-DPB1 Mismatching Compared to a Non-Permissive Mismatching Significantly Improves Overall Survival Following Allogeneic Transplantation In Patients with Both 10/10 and 9/10 Matched Unrelated Donors. Blood, 2010, 116, 227-227.	1.4	3
156	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica, 2009, 94, 1399-1406.	3.5	34
157	The impact of extramedullary disease at presentation on the outcome of myeloma. Leukemia and Lymphoma, 2009, 50, 230-235.	1.3	97
158	Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?. Haematologica, 2009, 94, 536-541.	3.5	63
159	A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC.. Blood, 2009, 114, 1205-1205.	1.4	5
160	The Presence of Minimal Residual Disease Pre- and Post-Transplant Is Predictive of Outcome in Recipients of Allogeneic Transplantation for Acute Myeloid Leukaemia.. Blood, 2009, 114, 2601-2601.	1.4	0
161	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. British Journal of Haematology, 2008, 141, 235-243.	2.5	44
162	Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. Blood Cells, Molecules, and Diseases, 2008, 40, 40-43.	1.4	12

#	ARTICLE	IF	CITATIONS
163	An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.. Blood, 2008, 112, 1149-1149.	1.4	0
164	Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation. Blood, 2008, 112, 3313-3313.	1.4	0
165	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. Blood, 2008, 112, 4413-4413.	1.4	0
166	A Single Institution's Experience with Allogeneic Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia: Analysis of Factors Leading to Improved Outcome. Blood, 2008, 112, 4322-4322.	1.4	0
167	TGFB1 Functional Polymorphisms: Impact on Outcome in Allogeneic Unrelated Donor Haematopoietic Stem Cell Transplantation. Blood, 2008, 112, 3011-3011.	1.4	20
168	Single Nucleotide Polymorphisms in the <i>NOD2/CARD15</i> Gene Are Associated With an Increased Risk of Relapse and Death for Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation With Unrelated Donors. Journal of Clinical Oncology, 2007, 25, 4262-4269.	1.6	58
169	The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood, 2007, 110, 4560-4566.	1.4	166
170	The Impact of Chimerism Patterns and Predonor Leukocyte Infusion Lymphopenia on Survival following T Cell-Depleted Reduced Intensity Conditioned Transplants. Biology of Blood and Marrow Transplantation, 2007, 13, 550-559.	2.0	24
171	Ifosfamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. British Journal of Haematology, 2007, 136, 752-761.	2.5	19
172	NOD2/CARD15 Genotype and HLA-DPB1 Matching Status Can Be Used To Predict Disease Relapse in Recipients of an Unrelated Donor Haematopoietic Stem Cell Transplant for Acute Leukaemia.. Blood, 2007, 110, 830-830.	1.4	1
173	Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation.. Blood, 2007, 110, 1999-1999.	1.4	0
174	HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood, 2006, 107, 1220-1226.	1.4	87
175	Low Pre-DLI Lymphocytes Counts Are Predictive of Good Disease Responses in Patients with Mixed Chimerism Following Campath-Containing Reduced Intensity Transplants.. Blood, 2006, 108, 261-261.	1.4	0
176	Ifosfamide, Etoposide and Epirubicin (IVE) Is an Effective Combined Salvage and Peripheral Blood Stem Cell Mobilisation Regimen for Transplant-Eligible Patients with Lymphoma.. Blood, 2006, 108, 2432-2432.	1.4	0
177	Single Nucleotide Polymorphisms of the NOD2/CARD15 Gene Are Associated with Significant Increases in Disease Relapse and Mortality in Recipients of an Unrelated Donor Haematopoietic Stem Cell Transplant for Acute Leukaemia.. Blood, 2006, 108, 498-498.	1.4	0
178	High Proportions of CD4+CD25hi T Cells Pretransplant Correlate with Worse Overall Survival after Stem Cell Transplant.. Blood, 2006, 108, 3126-3126.	1.4	0
179	Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. British Journal of Haematology, 2005, 129, 631-643.	2.5	109
180	Histologic Features of the Liver Biopsy Predict the Clinical Outcome for Patients with Graft-versus-Host Disease of the Liver. Biology of Blood and Marrow Transplantation, 2005, 11, 805-813.	2.0	37

#	ARTICLE	IF	CITATIONS
181	Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors.. Blood, 2005, 106, 2895-2895.	1.4	1
182	Converting Mixed Chimerism to Full Donor Chimerism in Recipients of Campath-Containing Reduced Intensity Transplants Reduces the Relapse Risk and Results in Significantly Improved Survival Compared to Those with Persistent Full Donor Chimerism.. Blood, 2005, 106, 2026-2026.	1.4	6
183	The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica, 2005, 90, 1562-9.	3.5	23
184	Matching Status at Amino Acid Positions 57 and 65 of the HLA-DPB1 Beta Chain Determines Outcome in Recipients of Unrelated Donor Haematopoietic Stem Cell Transplants.. Blood, 2004, 104, 827-827.	1.4	8
185	Increased Disease Relapse in HLA-DPB1 Matched Recipients of Unrelated Donor Transplants Is Not Confined to Pairs Matched for the Other Five HLA loci.. Blood, 2004, 104, 829-829.	1.4	1
186	Pathologic Features May Predict the Clinical Outcome of Hepatic Graft Versus Host Disease (H-GVHD).. Blood, 2004, 104, 5079-5079.	1.4	0
187	Progressive Arterial Thrombosis in a Patient with Non-Hodgkin's Lymphoma, a Lupus Anticoagulant, Factor V Leiden Mutation and Paraprotein, Following Chemotherapy. Leukemia and Lymphoma, 2001, 42, 221-223.	1.3	11